Arthrum 2.5% Single Injection

OVERVIEW

Arthrum 2.5% Single Injection is used to treat knee pain caused by Osteoarthritis (OA) in patients who have already been treated with pain relievers and other treatments that did not work well.

Arthrum 2.5% Single Injection is similar to a substance that occurs naturally in the joints and acts like a lubricant and shock absorber in the joints to help the joints work properly.

Arthrum 2.5% Single Injection is to be administered only by or under the immediate supervision of a doctor.

Common Example of Use

  • Knee pain caused by OA
  • Secondary knee OA due to traumas and joint fractures
  • When treatment with common pain relievers or other physical therapy does not provide adequate relief
  • Contraindications related to the placement of a prosthesis

Features + Benefits

  • The sodium hyaluronate is normally present in synovial fluid of healthy joints
  • The Arthrum 2.5% Single Injection has the effect of improving the characteristics of the synovial fluid (viscosity and elasticity) which are important for shock absorption and lubrication of the knees

Product Properties

  • New generation hyaluronic acid (HA)-based therapy for treating Osteoarthritis (OA) in a safe, easy-to-use, single injection regimen
  • Contains pure sodium hyaluronate and is not cross-linked by any chemical agent
  • Protective effect on cartilage by allowing joint surfaces to slide against each other and reduce stress on weight-bearing joints
  • Small molecules diffuse readily in the direction of the cartilage and synovial membrane
  • Sodium hyaluronate provides a protective barrier, masking the pain receptors of the synovial membrane
  • Complies with European Pharmacopoeia, ISO standards and EEC Directive 93/42, which guarantees the perfect safety and biocompatibility of the implantable device

Brochure

Dosage

  • Arthrum 2.5% Single Injection is supplied in a sterile disposable Luer-Lok syringe, prefilled with 3mL, in one syringe box
  • Arthrum 2.5% Single Injection has a high concentration of 25mg/mL (75mg per intra-articular injection)
  • The dosage schedule is one intra-articular injection in the knee
  • A second injection may be repeated between the 1st and 3rd month if justified by the painful symptoms of the patient